Rybrevant (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

RARITAN, New Jersey (March 01, 2024)– Johnson& Johnson (NYSE: JNJ) announced today that following a priority review, the U.S. Food and Drug Administration (FDA) has approved Rybrevant® (amivantamab-vmjw) in combination with...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news